Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reifenberger

Showing results (471-480 of 562) with videos related to

Pageof 57
Sort By:
The Journal of Clinical Investigation|April 10, 2008
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasStefan Pfister, Wibke G Janzarik, Marc Remke, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Journal of Neuro-Oncology|July 10, 2024
A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastasesSebastian Jeising, Ann-Christin Nickel, Johanna Trübel, et al.
Nature Communications|December 19, 2020
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtypeYonghe Wu, Michael Fletcher, Zuguang Gu, et al.
Acta Neuropathologica|August 14, 2012
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsXiao-Yang Liu, Noha Gerges, Andrey Korshunov, et al.
The Lancet. Oncology|August 30, 2024
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect groupPhilipp Karschnia, Jasper K W Gerritsen, Nico Teske, et al.
Journal of Neuro-Oncology|July 7, 2022
Mid-term treatment-related cognitive sequelae in glioma patientsSabine Schlömer, Jörg Felsberg, Milena Pertz, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
Acta Neuropathologica|October 21, 2015
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entityAndrey Korshunov, David Capper, David Reuss, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
Pageof 57

Showing results (471-480 of 562) with videos related to

Sort By:
Pageof 57
The Journal of Clinical Investigation|April 10, 2008
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasStefan Pfister, Wibke G Janzarik, Marc Remke, et al.
Neuro-Oncology|October 11, 2017
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylationTobias Kessler, Felix Sahm, Ahmed Sadik, et al.
Journal of Neuro-Oncology|July 10, 2024
A clinically compatible in vitro drug-screening platform identifies therapeutic vulnerabilities in primary cultures of brain metastasesSebastian Jeising, Ann-Christin Nickel, Johanna Trübel, et al.
Nature Communications|December 19, 2020
Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtypeYonghe Wu, Michael Fletcher, Zuguang Gu, et al.
Acta Neuropathologica|August 14, 2012
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutationsXiao-Yang Liu, Noha Gerges, Andrey Korshunov, et al.
The Lancet. Oncology|August 30, 2024
The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect groupPhilipp Karschnia, Jasper K W Gerritsen, Nico Teske, et al.
Journal of Neuro-Oncology|July 7, 2022
Mid-term treatment-related cognitive sequelae in glioma patientsSabine Schlömer, Jörg Felsberg, Milena Pertz, et al.
International Journal of Cancer|October 28, 2020
MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trialTheophilos Tzaridis, Niklas Schäfer, Johannes Weller, et al.
Acta Neuropathologica|October 21, 2015
Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entityAndrey Korshunov, David Capper, David Reuss, et al.
Neuro-Oncology|July 3, 2016
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomideWolfgang Wick, Patrick Roth, Christian Hartmann, et al.
Pageof 57